June 2, 2009 - Naviscan Inc. has issued a nonexclusive licensing agreement with an undisclosed imaging company for intellectual property that enables Naviscan’s Stereo Navigator PEM-guided biopsy accessory to obtain emission data, locate the abnormal tissue and process the data to guide a biopsy needle.
This is the second licensing agreement based on Naviscan’s intellectual property portfolio, reinforces Naviscan’s leadership position in molecular breast imaging (MBI). The company is currently negotiating licensing agreements with other diagnostic imaging companies and expects these agreements to be signed as early as the third quarter of 2009.
The new licensing agreement covers the use of Stereo Navigator, a medical method and apparatus for the localization and biopsy of lesions. This patent enables PET scanners and gamma cameras to obtain emission data, locate the abnormal tissue and process the data to best guide a biopsy needle to acquire a sample of the abnormal tissue. The previous licensing agreement concerned a method and apparatus patent enabling the immobilization and compression of a body part for the purposes of collecting PET or gamma emission data in an effort to create a physiological image of the body part.
Naviscan currently has four other patents pending.
Naviscan was recently awarded Frost & Sullivan’s 2009 “Emerging Technology of the Year.”
For more information: www.naviscan.com